MedTrace Logo

A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects

NCT01664065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-09-05

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of Ceftaroline in a group of patients with renal disease and matching healthy subjects with normal renal function

Conditions

  • Renal Disease

Interventions

DRUG

200 mg Ceftaroline fosamil

1 h infusion

DRUG

600 mg Ceftaroline fosamil

1 h infusion

Sponsors & Collaborators

Principal Investigators

  • David Melnick, MD · AstraZeneca Pharmaceuticals;C2C-716 1800 Concord PikePO. Box 15437Wilmington De 19850-5437

  • Arpeat Kaviya, MBChB, MRCP · Quintiles Drug Research Unit at Guy's Hospital 6 Newcomen St

  • Mirjana Kujacic, MD · AstraZeneca Research and Development SE-431 83 Mölndal

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664065 on ClinicalTrials.gov